258 related articles for article (PubMed ID: 27986599)
1. Development of a Novel Formulation That Improves Preclinical Bioavailability of Tenofovir Disoproxil Fumarate.
Watkins ME; Wring S; Randolph R; Park S; Powell K; Lutz L; Nowakowski M; Ramabhadran R; Domanico PL
J Pharm Sci; 2017 Mar; 106(3):906-919. PubMed ID: 27986599
[TBL] [Abstract][Full Text] [Related]
2. Effects of human immunodeficiency virus protease inhibitors on the intestinal absorption of tenofovir disoproxil fumarate in vitro.
Tong L; Phan TK; Robinson KL; Babusis D; Strab R; Bhoopathy S; Hidalgo IJ; Rhodes GR; Ray AS
Antimicrob Agents Chemother; 2007 Oct; 51(10):3498-504. PubMed ID: 17664327
[TBL] [Abstract][Full Text] [Related]
3. Intestinal absorption enhancement of the ester prodrug tenofovir disoproxil fumarate through modulation of the biochemical barrier by defined ester mixtures.
van Gelder J; Deferme S; Naesens L; De Clercq E; van den Mooter G; Kinget R; Augustijns P
Drug Metab Dispos; 2002 Aug; 30(8):924-30. PubMed ID: 12124311
[TBL] [Abstract][Full Text] [Related]
4. Intestinal behavior of the ester prodrug tenofovir DF in humans.
Geboers S; Haenen S; Mols R; Brouwers J; Tack J; Annaert P; Augustijns P
Int J Pharm; 2015 May; 485(1-2):131-7. PubMed ID: 25747454
[TBL] [Abstract][Full Text] [Related]
5. Chitosan nanoparticles for the oral delivery of tenofovir disoproxil fumarate: formulation optimization, characterization and ex vivo and in vivo evaluation for uptake mechanism in rats.
Shailender J; Ravi PR; Reddy Sirukuri M; Dalvi A; Keerthi Priya O
Drug Dev Ind Pharm; 2018 Jul; 44(7):1109-1119. PubMed ID: 29409342
[TBL] [Abstract][Full Text] [Related]
6. Role of drug efflux and uptake transporters in atazanavir intestinal permeability and drug-drug interactions.
Kis O; Zastre JA; Hoque MT; Walmsley SL; Bendayan R
Pharm Res; 2013 Apr; 30(4):1050-64. PubMed ID: 23224979
[TBL] [Abstract][Full Text] [Related]
7. Interactions of tenofovir and tenofovir disoproxil fumarate with drug efflux transporters ABCB1, ABCG2, and ABCC2; role in transport across the placenta.
Neumanova Z; Cerveny L; Ceckova M; Staud F
AIDS; 2014 Jan; 28(1):9-17. PubMed ID: 24413260
[TBL] [Abstract][Full Text] [Related]
8. Oral pharmacokinetic interaction of ester rich fruit juices and pharmaceutical excipients with tenofovir disoproxil fumarate in male Wistar rats.
Shailender J; Ravi PR; Saha P; Myneni S
Xenobiotica; 2017 Dec; 47(12):1104-1111. PubMed ID: 27921450
[TBL] [Abstract][Full Text] [Related]
9. Differential Mechanisms of Tenofovir and Tenofovir Disoproxil Fumarate Cellular Transport and Implications for Topical Preexposure Prophylaxis.
Taneva E; Crooker K; Park SH; Su JT; Ott A; Cheshenko N; Szleifer I; Kiser PF; Frank B; Mesquita PM; Herold BC
Antimicrob Agents Chemother; 2015 Dec; 60(3):1667-75. PubMed ID: 26711762
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of intestinal metabolism of the antiviral ester prodrug bis(POC)-PMPA by nature-identical fruit extracts as a strategy to enhance its oral absorption: an in vitro study.
Van Gelder J; Annaert P; Naesens L; De Clercq E; Van den Mooter G; Kinget R; Augustijns P
Pharm Res; 1999 Jul; 16(7):1035-40. PubMed ID: 10450927
[TBL] [Abstract][Full Text] [Related]
11. In Vitro Virology Profile of Tenofovir Alafenamide, a Novel Oral Prodrug of Tenofovir with Improved Antiviral Activity Compared to That of Tenofovir Disoproxil Fumarate.
Callebaut C; Stepan G; Tian Y; Miller MD
Antimicrob Agents Chemother; 2015 Oct; 59(10):5909-16. PubMed ID: 26149992
[TBL] [Abstract][Full Text] [Related]
12. Effect of P-glycoprotein and Cotreatment with Sofosbuvir on the Intestinal Permeation of Tenofovir Disoproxil Fumarate and Tenofovir Alafenamide Fumarate.
Huliciak M; Lhotska I; Kocova-Vlckova H; Halodova V; Dusek T; Cecka F; Staud F; Vokral I; Cerveny L
Pharm Res; 2023 Sep; 40(9):2109-2120. PubMed ID: 37594591
[TBL] [Abstract][Full Text] [Related]
13. Solid Forms of Tenofovir Disoproxil Fumarate, Their Mutual Conversion, and Stabilization of Form I in Formulation.
Sládková V; Dammer O; Kratochvíl B
J Pharm Sci; 2016 Oct; 105(10):3136-3142. PubMed ID: 27522525
[TBL] [Abstract][Full Text] [Related]
14. Stability behaviour of antiretroviral drugs and their combinations. 4: Characterization of degradation products of tenofovir alafenamide fumarate and comparison of its degradation and stability behaviour with tenofovir disoproxil fumarate.
Golla VM; Kurmi M; Shaik K; Singh S
J Pharm Biomed Anal; 2016 Nov; 131():146-155. PubMed ID: 27589032
[TBL] [Abstract][Full Text] [Related]
15. Species-dependent and site-specific intestinal metabolism of ester prodrugs.
Van Gelder J; Shafiee M; De Clercq E; Penninckx F; Van den Mooter G; Kinget R; Augustijns P
Int J Pharm; 2000 Sep; 205(1-2):93-100. PubMed ID: 11000545
[TBL] [Abstract][Full Text] [Related]
16. Nucleotide analogue prodrug tenofovir disoproxil enhances lymphoid cell loading following oral administration in monkeys.
Durand-Gasselin L; Van Rompay KK; Vela JE; Henne IN; Lee WA; Rhodes GR; Ray AS
Mol Pharm; 2009; 6(4):1145-51. PubMed ID: 19545170
[TBL] [Abstract][Full Text] [Related]
17. Improved pharmacokinetics of tenofovir ester prodrugs strengthened the inhibition of HBV replication and the rebalance of hepatocellular metabolism in preclinical models.
Hong X; Cai Z; Zhou F; Jin X; Wang G; Ouyang B; Zhang J
Front Pharmacol; 2022; 13():932934. PubMed ID: 36105197
[TBL] [Abstract][Full Text] [Related]
18. Profiling the Interaction between Human Serum Albumin and Clinically Relevant HIV Reverse Transcriptase Inhibitors.
Costa-Tuna A; Chaves OA; Almeida ZL; Cunha RS; Pina J; Serpa C
Viruses; 2024 Mar; 16(4):. PubMed ID: 38675834
[TBL] [Abstract][Full Text] [Related]
19. Simulating Intestinal Transporter and Enzyme Activity in a Physiologically Based Pharmacokinetic Model for Tenofovir Disoproxil Fumarate.
Moss DM; Domanico P; Watkins M; Park S; Randolph R; Wring S; Rajoli RKR; Hobson J; Rannard S; Siccardi M; Owen A
Antimicrob Agents Chemother; 2017 Jul; 61(7):. PubMed ID: 28416547
[TBL] [Abstract][Full Text] [Related]
20. High resistance barrier to tenofovir alafenamide is driven by higher loading of tenofovir diphosphate into target cells compared to tenofovir disoproxil fumarate.
Margot NA; Liu Y; Miller MD; Callebaut C
Antiviral Res; 2016 Aug; 132():50-8. PubMed ID: 27208653
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
